EG24459A - Soluble CTLA4 mutant molecules and uses thereof - Google Patents

Soluble CTLA4 mutant molecules and uses thereof

Info

Publication number
EG24459A
EG24459A EG20010548A EG20010548A EG24459A EG 24459 A EG24459 A EG 24459A EG 20010548 A EG20010548 A EG 20010548A EG 20010548 A EG20010548 A EG 20010548A EG 24459 A EG24459 A EG 24459A
Authority
EG
Egypt
Prior art keywords
soluble ctla4
mutant molecules
amino acid
ctla4
molecules
Prior art date
Application number
EG20010548A
Other languages
English (en)
Inventor
Robert J Peach
Joseph R Naemura
Peter S Linsley
Juergen Bajorath
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of EG24459A publication Critical patent/EG24459A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EG20010548A 2000-05-26 2001-05-23 Soluble CTLA4 mutant molecules and uses thereof EG24459A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
EG24459A true EG24459A (en) 2009-07-16

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010548A EG24459A (en) 2000-05-26 2001-05-23 Soluble CTLA4 mutant molecules and uses thereof

Country Status (41)

Country Link
EP (3) EP1248802B9 (hr)
JP (1) JP4328525B2 (hr)
KR (2) KR100889887B1 (hr)
CN (2) CN1309735C (hr)
AR (1) AR031699A1 (hr)
AT (1) ATE271066T1 (hr)
AU (2) AU2001263466C1 (hr)
BE (1) BE2011C041I2 (hr)
BR (1) BRPI0111191B8 (hr)
CA (1) CA2409748C (hr)
CY (2) CY2011019I2 (hr)
CZ (1) CZ304451B6 (hr)
DE (2) DE60104282T2 (hr)
DK (1) DK1248802T3 (hr)
EC (1) ECSP024365A (hr)
EE (2) EE05458B1 (hr)
EG (1) EG24459A (hr)
ES (2) ES2225549T3 (hr)
FR (1) FR11C0053I2 (hr)
GE (1) GEP20053658B (hr)
HK (2) HK1048126B (hr)
HU (2) HU228137B1 (hr)
IL (1) IL152315A (hr)
LT (1) LT5133B (hr)
LU (1) LU91902I2 (hr)
LV (1) LV12994B (hr)
MX (1) MXPA02011534A (hr)
MY (1) MY136113A (hr)
NO (2) NO330797B1 (hr)
PE (1) PE20011338A1 (hr)
PL (1) PL206267B1 (hr)
PT (1) PT1248802E (hr)
RU (1) RU2283847C2 (hr)
SI (1) SI1248802T1 (hr)
SK (1) SK288131B6 (hr)
TR (1) TR200402703T4 (hr)
TW (2) TWI314933B (hr)
UA (1) UA87432C2 (hr)
UY (1) UY26723A1 (hr)
WO (1) WO2001092337A2 (hr)
ZA (1) ZA200208944B (hr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1935427B1 (en) * 2000-07-03 2018-03-07 Bristol-Myers Squibb Company Uses of soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
WO2002094202A2 (en) 2001-05-23 2002-11-28 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
SI1576182T2 (sl) 2002-12-23 2020-07-31 Bristol-Myers Squibb Company Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
ES2439641T3 (es) * 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
WO2008076487A2 (en) 2006-12-20 2008-06-26 Verenium Corporation Antibodies and methods for making and using them
PL2222697T3 (pl) 2007-11-01 2013-05-31 Astellas Pharma Inc Immunosupresyjne polipeptydy i kwasy nukleinowe
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
KR20130049775A (ko) * 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
US20120214204A1 (en) 2011-02-23 2012-08-23 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
AU2013260172B2 (en) 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CN104519900A (zh) * 2012-06-27 2015-04-15 欧尔本生物科技有限责任公司 用于治疗糖尿病的ctla4融合蛋白
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
JP6732660B2 (ja) 2014-01-13 2020-07-29 アムジエン・インコーポレーテツド 組換えタンパク質の高マンノースグリコフォーム含有量を操作するためのオルニチン代謝の調節
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
FI3926051T3 (fi) 2014-06-04 2024-06-18 Amgen Inc Menetelmiä nisäkässoluviljelmien keräämiseksi
LT3227454T (lt) 2014-12-01 2020-07-27 Amgen Inc. Glikoproteino glikano sudedamosios dalies kiekio keitimo procedūra
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
KR20180012260A (ko) 2015-04-17 2018-02-05 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 친화성을 갖는 면역조절 단백질
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
CN108350416A (zh) 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
CA3036997A1 (en) * 2016-09-19 2018-03-22 Oncoimmune, Inc. Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
CN116732106A (zh) 2017-04-20 2023-09-12 E开创生物技术股份有限公司 产生基因修改的动物的方法
MA50360A (fr) * 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
MX2022002337A (es) 2019-08-27 2022-06-08 Tonix Pharma Ltd Polipéptidos de tff2 modificados.
US11098311B2 (en) 2019-12-06 2021-08-24 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US20210396764A1 (en) 2020-06-18 2021-12-23 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed c-terminal lysine
CA3189533A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
WO2023115027A2 (en) 2021-12-16 2023-06-22 Bristol-Myers Squibb Company Detergent for viral inactivation
US20230287043A1 (en) 2022-03-02 2023-09-14 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ATE170562T1 (de) 1991-06-27 1998-09-15 Bristol Myers Squibb Co Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
WO2000019988A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
EP1935427B1 (en) * 2000-07-03 2018-03-07 Bristol-Myers Squibb Company Uses of soluble CTLA4 mutant molecules

Also Published As

Publication number Publication date
EE201100050A (et) 2011-10-17
CA2409748A1 (en) 2001-12-06
ES2571852T3 (es) 2016-05-27
JP2004511213A (ja) 2004-04-15
LV12994B (en) 2003-08-20
FR11C0053I2 (fr) 2013-01-11
HUP0302201A2 (hu) 2003-10-28
NO2011027I1 (no) 2012-01-09
EP1536234B1 (en) 2016-03-16
AU6346601A (en) 2001-12-11
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
KR100889887B1 (ko) 2009-03-24
NO20025656D0 (no) 2002-11-25
SK15702002A3 (sk) 2004-01-08
ES2225549T3 (es) 2005-03-16
KR100895134B1 (ko) 2009-05-04
NO2011027I2 (hr) 2011-12-15
LT5133B (lt) 2004-05-25
UA87432C2 (uk) 2009-07-27
CY2011019I1 (el) 2016-12-14
ECSP024365A (es) 2003-03-31
HUS1300012I1 (hu) 2016-08-29
SI1248802T1 (en) 2005-02-28
CN1309735C (zh) 2007-04-11
HU228137B1 (en) 2012-12-28
DK1248802T3 (da) 2004-11-15
GEP20053658B (en) 2005-11-10
EP1248802B1 (en) 2004-07-14
BRPI0111191B8 (pt) 2021-05-25
KR20030009502A (ko) 2003-01-29
BRPI0111191B1 (pt) 2019-12-31
EP1536234A3 (en) 2009-06-03
HK1071931A1 (zh) 2005-08-05
EP3029062A1 (en) 2016-06-08
DE60104282T2 (de) 2005-10-13
EE05458B1 (et) 2011-08-15
PE20011338A1 (es) 2002-01-13
ATE271066T1 (de) 2004-07-15
AU2001263466C1 (en) 2006-10-26
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
EE05557B1 (et) 2012-08-15
TWI314933B (en) 2009-09-21
CZ20023892A3 (cs) 2003-09-17
EP1536234A2 (en) 2005-06-01
EP1248802B9 (en) 2005-05-11
TWI319405B (en) 2010-01-11
HK1048126A1 (en) 2003-03-21
MY136113A (en) 2008-08-29
HK1048126B (zh) 2005-03-04
MXPA02011534A (es) 2004-08-12
PT1248802E (pt) 2004-11-30
AU2001263466B2 (en) 2006-04-27
BR0111191A (pt) 2004-07-06
UY26723A1 (es) 2001-12-28
CA2409748C (en) 2008-09-16
BE2011C041I2 (hr) 2020-08-20
CY1117625T1 (el) 2017-04-26
HUP0302201A3 (en) 2010-01-28
NO330797B1 (no) 2011-07-18
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
PL366231A1 (en) 2005-01-24
JP4328525B2 (ja) 2009-09-09
AR031699A1 (es) 2003-10-01
TW200906857A (en) 2009-02-16
CN1441810A (zh) 2003-09-10
PL206267B1 (pl) 2010-07-30
LT2002114A (en) 2003-12-29
WO2001092337A2 (en) 2001-12-06
ZA200208944B (en) 2004-02-13
EE200200659A (et) 2004-06-15
IL152315A0 (en) 2003-05-29
RU2283847C2 (ru) 2006-09-20
IL152315A (en) 2010-04-15
CN101255192A (zh) 2008-09-03
CZ304451B6 (cs) 2014-05-14
NO20025656L (no) 2002-11-25
FR11C0053I1 (hr) 2012-01-13
TR200402703T4 (tr) 2004-11-22
DE60104282D1 (de) 2004-08-19
DE122011100063I1 (de) 2012-06-14

Similar Documents

Publication Publication Date Title
TWI319405B (en) Soluble ctla4 mutant molecules and uses thereof
MX339406B (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
SG156547A1 (en) Human monoclonal antibodies to ctla-4
EP1559795A3 (en) Neisseria genomic sequences and methods of their use
AU3877500A (en) Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
MX2007012222A (es) Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.
WO2003025119A3 (en) Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies